Accession Therapeutics
4:45 PM - 5:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
Accession Therapeutics is developing a new generation of immunotherapies for solid tumors.
Accession Therapeutics aims to address tumor diversity using its highly potent universal bispecific drugs, expressed only in cancer cells.
Company objectives: deliver first-in-human clinical trials 1H 2024 and seek a partnership for later stage trials and commercialisation.
We aim to deliver a step change in cancer treatments for patients with solid tumors.
Accession Therapeutics aims to address tumor diversity using its highly potent universal bispecific drugs, expressed only in cancer cells.
Company objectives: deliver first-in-human clinical trials 1H 2024 and seek a partnership for later stage trials and commercialisation.
We aim to deliver a step change in cancer treatments for patients with solid tumors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2021
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Trocept 1
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
